Pomanda estimates the enterprise value of MYLAN PHARMA UK LIMITED at £105.7m based on a Turnover of £44.1m and 2.4x industry multiple (adjusted for size and gross margin).
mylan pharma uk limitedEstimated Valuation
£50.4m
Pomanda estimates the enterprise value of MYLAN PHARMA UK LIMITED at £50.4m based on an EBITDA of £4.4m and a 11.36x industry multiple (adjusted for size and gross margin).
mylan pharma uk limitedEstimated Valuation
£80.2m
Pomanda estimates the enterprise value of MYLAN PHARMA UK LIMITED at £80.2m based on Net Assets of £41.7m and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Mylan Pharma Uk LimitedOverview
Mylan Pharma Uk Limited is a live company located in hertfordshire, EN6 1TL with a Companies House number of 07838949. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in November 2011, it's largest shareholder is
mcdermott laboratories ltd
with a 100% stake. Mylan Pharma Uk Limited is a established,
large sized company, Pomanda has estimated its turnover at
£44.1m with
unknown
growth in recent years.
Pomanda's financial health check has awarded Mylan Pharma Uk Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 1 areas for improvement. Company Health Check FAQs
Health Rating5out of 5
7 Strong
1 Regular
1 Weak
Size
annual sales of £44.1m, make it larger than the average company (£4.4m)
£44.1m - Mylan Pharma Uk Limited
£4.4m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- - Mylan Pharma Uk Limited
- - Industry AVG
Production
with a gross margin of 46.6%, this company has a comparable cost of product (46.6%)
46.6% - Mylan Pharma Uk Limited
46.6% - Industry AVG
Profitability
an operating margin of 8.9% make it more profitable than the average company (3.6%)
8.9% - Mylan Pharma Uk Limited
3.6% - Industry AVG
Employees
with 97 employees, this is above the industry average (46)
97 - Mylan Pharma Uk Limited
46 - Industry AVG
Pay Structure
on an average salary of £133.3k, the company has a higher pay structure (£64.5k)
£133.3k - Mylan Pharma Uk Limited
£64.5k - Industry AVG
Efficiency
resulting in sales per employee of £454.2k, this is more efficient (£123.2k)
£454.2k - Mylan Pharma Uk Limited
£123.2k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Mylan Pharma Uk Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 65 days, this is slower than average (44 days)
65 days - Mylan Pharma Uk Limited
44 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Mylan Pharma Uk Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 178 weeks, this is more cash available to meet short term requirements (31 weeks)
178 weeks - Mylan Pharma Uk Limited
31 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 22%, this is a lower level of debt than the average (44.4%)
22% - Mylan Pharma Uk Limited
44.4% - Industry AVG
MYLAN PHARMA UK LIMITED financials
EXPORT
Mylan Pharma Uk Limited's latest turnover from December 2023 is £44.1 million and the company has net assets of £41.7 million. According to their latest financial statements, Mylan Pharma Uk Limited has 97 employees and maintains cash reserves of £39.1 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Turnover
44,059,000
33,738,000
35,184,000
Other Income Or Grants
Cost Of Sales
23,521,026
17,835,892
18,940,644
Gross Profit
20,537,974
15,902,108
16,243,356
Admin Expenses
16,599,974
13,379,108
14,391,356
15,698,000
16,874,000
35,566,000
70,798,000
108,366,000
97,551,000
66,118,000
28,807,000
25,168,000
Operating Profit
3,938,000
2,523,000
1,852,000
-15,698,000
-16,874,000
-35,566,000
-70,798,000
-108,366,000
-97,551,000
-66,118,000
-28,807,000
-25,168,000
Interest Payable
1,263,000
35,000
59,000
941,000
6,000
9,000
123,000
38,000
24,000
52,000
Interest Receivable
2,016,000
589,000
45,000
330,000
420,000
231,000
121,000
81,000
46,000
6,000
6,000
1,000
Pre-Tax Profit
5,954,000
1,849,000
1,862,000
725,000
-2,726,000
5,538,000
-960,000
11,096,000
9,915,000
6,870,000
3,123,000
2,312,000
Tax
-1,454,000
127,000
-248,000
-219,000
-148,000
-875,000
42,000
282,000
-844,000
-1,770,000
-257,000
Profit After Tax
4,500,000
1,976,000
1,614,000
506,000
-2,874,000
4,663,000
-918,000
11,378,000
9,071,000
5,100,000
2,866,000
2,312,000
Dividends Paid
Retained Profit
4,500,000
1,976,000
1,614,000
506,000
-2,874,000
4,663,000
-918,000
11,378,000
9,071,000
5,100,000
2,866,000
2,312,000
Employee Costs
12,930,000
11,468,000
10,483,000
10,402,000
10,295,000
11,269,000
12,637,000
12,573,000
11,244,000
9,169,000
7,092,000
5,318,000
Number Of Employees
97
90
88
84
90
114
141
142
119
97
75
66
EBITDA*
4,440,000
3,006,000
2,343,000
-15,132,000
-16,225,000
-34,598,000
-68,529,000
-106,955,000
-96,608,000
-65,374,000
-28,178,000
-24,951,000
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Tangible Assets
1,839,000
1,906,000
1,867,000
1,846,000
2,309,000
2,802,000
7,147,000
8,032,000
7,937,000
7,782,000
4,278,000
3,809,000
Intangible Assets
4,000
15,000
27,000
38,000
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
1,839,000
1,906,000
1,867,000
1,846,000
2,309,000
2,802,000
7,147,000
8,032,000
7,941,000
7,797,000
4,305,000
3,847,000
Stock & work in progress
Trade Debtors
71,000
Group Debtors
11,116,000
12,817,000
12,013,000
16,936,000
29,598,000
27,854,000
17,814,000
Misc Debtors
1,328,000
2,139,000
1,769,000
2,182,000
2,186,000
4,048,000
6,562,000
6,600,000
11,406,000
13,111,000
1,760,000
1,817,000
Cash
39,108,000
42,398,000
33,155,000
15,688,000
3,438,000
6,997,000
12,974,000
20,900,000
35,085,000
1,177,000
4,636,000
1,624,000
misc current assets
3,000
total current assets
51,552,000
57,354,000
46,937,000
34,877,000
35,222,000
38,899,000
37,350,000
27,503,000
46,491,000
14,288,000
6,396,000
3,441,000
total assets
53,391,000
59,260,000
48,804,000
36,723,000
37,531,000
41,701,000
44,497,000
35,535,000
54,432,000
22,085,000
10,701,000
7,288,000
Bank overdraft
Bank loan
Trade Creditors
4,214,000
3,915,000
14,458,000
1,238,000
1,678,000
1,575,000
1,631,000
Group/Directors Accounts
1,063,000
13,881,000
248,000
1,163,000
11,082,000
other short term finances
hp & lease commitments
other current liabilities
6,090,000
4,842,000
2,659,000
3,752,000
5,652,000
11,892,000
4,806,000
23,999,000
11,805,000
5,521,000
4,975,000
total current liabilities
11,367,000
22,638,000
14,458,000
4,145,000
5,430,000
7,227,000
14,686,000
4,806,000
35,081,000
11,805,000
5,521,000
4,975,000
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
363,000
321,000
626,000
472,000
501,000
total long term liabilities
363,000
321,000
626,000
472,000
501,000
total liabilities
11,730,000
22,959,000
15,084,000
4,617,000
5,931,000
7,227,000
14,686,000
4,806,000
35,081,000
11,805,000
5,521,000
4,975,000
net assets
41,661,000
36,301,000
33,720,000
32,106,000
31,600,000
34,474,000
29,811,000
30,729,000
19,351,000
10,280,000
5,180,000
2,313,000
total shareholders funds
41,661,000
36,301,000
33,720,000
32,106,000
31,600,000
34,474,000
29,811,000
30,729,000
19,351,000
10,280,000
5,180,000
2,313,000
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Operating Activities
Operating Profit
3,938,000
2,523,000
1,852,000
-15,698,000
-16,874,000
-35,566,000
-70,798,000
-108,366,000
-97,551,000
-66,118,000
-28,807,000
-25,168,000
Depreciation
502,000
483,000
491,000
566,000
649,000
968,000
2,269,000
1,407,000
932,000
732,000
618,000
209,000
Amortisation
4,000
11,000
12,000
11,000
8,000
Tax
-1,454,000
127,000
-248,000
-219,000
-148,000
-875,000
42,000
282,000
-844,000
-1,770,000
-257,000
Stock
Debtors
-2,512,000
1,174,000
-5,407,000
-12,595,000
-118,000
7,526,000
17,776,000
-4,806,000
-1,705,000
11,351,000
-57,000
1,817,000
Creditors
299,000
-10,543,000
13,220,000
-440,000
103,000
-56,000
1,631,000
Accruals and Deferred Income
1,248,000
4,842,000
-2,659,000
-1,093,000
-1,900,000
-6,240,000
7,086,000
-19,193,000
12,194,000
6,284,000
546,000
4,975,000
Deferred Taxes & Provisions
42,000
-305,000
154,000
-29,000
501,000
Cash flow from operations
7,087,000
-4,047,000
18,217,000
-4,318,000
-17,551,000
-49,295,000
-77,546,000
-121,060,000
-83,553,000
-72,211,000
-27,832,000
-21,793,000
Investing Activities
capital expenditure
-435,000
-522,000
-512,000
-103,000
-156,000
3,377,000
-1,384,000
-1,502,000
-1,087,000
-4,236,000
-1,087,000
-4,064,000
Change in Investments
cash flow from investments
-435,000
-522,000
-512,000
-103,000
-156,000
3,377,000
-1,384,000
-1,502,000
-1,087,000
-4,236,000
-1,087,000
-4,064,000
Financing Activities
Bank loans
Group/Directors Accounts
-12,818,000
13,881,000
-248,000
248,000
-1,163,000
1,163,000
-11,082,000
11,082,000
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
860,000
605,000
1,000
1,000
interest
2,016,000
-674,000
10,000
271,000
-521,000
225,000
112,000
-42,000
8,000
-18,000
6,000
-51,000
cash flow from financing
-9,942,000
13,812,000
-238,000
519,000
-521,000
-938,000
1,275,000
-11,124,000
11,090,000
-18,000
7,000
-50,000
cash and cash equivalents
cash
-3,290,000
9,243,000
17,467,000
12,250,000
-3,559,000
-5,977,000
-7,926,000
-14,185,000
33,908,000
-3,459,000
3,012,000
1,624,000
overdraft
change in cash
-3,290,000
9,243,000
17,467,000
12,250,000
-3,559,000
-5,977,000
-7,926,000
-14,185,000
33,908,000
-3,459,000
3,012,000
1,624,000
mylan pharma uk limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for mylan pharma uk limited. Get real-time insights into mylan pharma uk limited's credit score, group structure and payment trends.
Perform a competitor analysis for mylan pharma uk limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other large companies, companies in EN6 area or any other competitors across 12 key performance metrics.
mylan pharma uk limited Ownership
MYLAN PHARMA UK LIMITED group structure
Mylan Pharma Uk Limited has no subsidiary companies.
Ultimate parent company
MYLAN NV
#0066723
MCDERMOTT LABORATORIES LIMITED
IE110075
2 parents
MYLAN PHARMA UK LIMITED
07838949
MYLAN PHARMA UK LIMITED Shareholders
The sole shareholder of Mylan Pharma Uk Limited is Mcdermott Laboratories Ltd.
mcdermott laboratories ltd
100%
mylan pharma uk limited directors
Mylan Pharma Uk Limited currently has 3 directors.
The longest serving directors include
Ms Caroline Dixon (Apr 2012) and
Dr Walter Cook (Jun 2017).
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
November 2011
age
14
incorporated
UK
ultimate parent company
MYLAN NV
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
DELOITTE LLP
address
20 station close, potters bar, hertfordshire, EN6 1TL
Bank
-
Legal Advisor
-
mylan pharma uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to mylan pharma uk limited.
mylan pharma uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for MYLAN PHARMA UK LIMITED. This can take several minutes, an email will notify you when this has completed.
mylan pharma uk limitedCompanies House Filings - See Documents
